MLN9708 (Ixazomib) and MLN4924 (Pevonedistat) in Relapsed/Refractory Multiple Myeloma Patients: A Phase 1b Trial
What is the purpose of this trial?
This IB trial studies side effects and best dose of pevonedistat when given together with ixazomib in treating patients with multiple myeloma that has come or does not respond to treatment. Pevonedistat and ixazomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Trial withNational Cancer Institute (NCI)
- Start Date01/06/2020
- End Date09/29/2021
- Last Updated01/08/2020
- Study HIC#2000025996